Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System
ICI-induced atrial fibrillation was serious and had severe outcomes. The anti-CTLA-4 showed a lower likelihood of reporting atrial fibrillation, while higher reporting was found with anti-PD-1 and anti-PD-L1. Further studies are needed to confirm this safety aspect.
Authors
- Annalisa Capuano (ORCID: https://orcid.org/0000-0002-8653-2408)
- Concetta Rafaniello (ORCID: https://orcid.org/0000-0002-7107-4280)
- Donatella Ruggiero
- Annamaria Mascolo (ORCID: https://orcid.org/0000-0003-2554-0065)
- Nunzia Balzano
- Giuseppe Paolisso (ORCID: https://orcid.org/0000-0002-2137-455X)
- Francesco Rossi
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Regione Campania (IT)
- Saint Camillus International University of Health and Medical Sciences (IT)
- Link Campus University (IT)
Publication Details
- Journal
- Therapeutic Advances in Drug Safety
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1177/20420986241312497
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05